UAB Digital Repository of Documents 10 records found  Search took 0.01 seconds. 
1.
4 p, 736.7 KB Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia / Genescà, E. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lazarenkov, A. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Morgades, Mireia. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Berbis, G. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ruíz-Xivillé, N. (Universitat Autònoma de Barcelona (UAB). Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona) ; Gómez-Marzo, P. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, J. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Juncà, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; González-Pérez, A. (Universitat Pompeu Fabra. Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Research Program on Biomedical Informatics) ; Mercadal, S. (Clinical Hematology Service, Hospital Duran i Reynals-ICO, Hospitalet del LLobregat) ; Guardia, R. (Clinical Hematology Service, Hospital Josep Trueta-ICO, Girona, Spain) ; Artola, M. T. (Hospital Universitario de Donostia. Clinical Hematology Service) ; Moreno, M. J. (Clinical Hematology Service, Hospital Vírgen de la Victoria) ; Martínez-López, J. (Universidad Complutense. Hematology Department, Hospital 12 de Octubre, CNIO) ; Zamora, L. (Universitat Autònoma de Barcelona (UAB). Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona) ; Barba, P. (VHIO) ; Gil, Cristina (Clinical Hematology Service, Hospital General de Alicante) ; Tormo, M. (Clinical Hematology Service, Hospital Clínico de Valencia) ; Cladera, A. (Clinical Hematology Service, Hospital Son Llàtzer) ; Novo, A. (Clinical Hematology Service, Hospital Son Espases) ; Pratcorona, M. (Institut d'Investigació Biomèdica Sant Pau) ; Nomdedeu, J. (Institut d'Investigació Biomèdica Sant Pau) ; González-Campos, J. (Clinical Hematology Service, Hospital Vírgen del Rocío) ; Almeida, M. (Universidad de Salamanca. Banco Nacional de ADN Carlos III) ; Cervera, J. (Biobanco de la Fe, Instituto de Investigación Sanitaria La Fe (IIS La Fe)) ; Montesinos, Pau (Clinical Hematology Service, Hospital La Fe) ; Batlle, M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Vives, S. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Esteve, J. (Clinical Hematology Service, Hospital Clínic de Barcelona) ; Feliu, E. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solé, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Orfao, A. (Hospital Clínico Universitario de Salamanca (HUS), Instituto Bio-Sanitario de Salamanca (IBSAL), CIBERONC. Centro de Investigación del Cáncer (IBMCC-CSIC/USAL) (CIC)) ; Ribera, J. M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. [...]
2018 - 10.1186/s13045-018-0639-8
Journal of hematology & oncology, Vol. 11 (july 2018)  
2.
12 p, 548.1 KB Mosaicism in Fanconi anemia : concise review and evaluation of published cases with focus on clinical course of blood count normalization / Nicoletti, Eileen (Rocket Pharmaceuticals, Inc., New York) ; Rao, Gayatri (Rocket Pharmaceuticals, Inc., New York, NY USA) ; Bueren, Juan A. (Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz) ; Río, Paula (Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz) ; Navarro, Susana (Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz) ; Surrallés, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Choi, Grace (Rocket Pharmaceuticals, Inc., New York) ; Schwartz, Jonathan D. (Rocket Pharmaceuticals, Inc., New York) ; Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia
Fanconi anemia (FA) is a DNA repair disorder resulting from mutations in genes encoding for FA DNA repair complex components and is characterized by variable congenital abnormalities, bone marrow failure (BMF), and high incidences of malignancies. [...]
2020 - 10.1007/s00277-020-03954-2
Annals of Hematology, Vol. 99 (february 2020) , p. 913-924  
3.
19 p, 21.3 MB An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination / Pallarès, Víctor (Institut d'Investigació Biomèdica Sant Pau) ; Unzueta Elorza, Ugutz (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Falgàs Comamala, Aïda (Institut d'Investigació Biomèdica Sant Pau) ; Sánchez García, Laura (Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Serna, Naroa (Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Gallardo, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Morris, Gordon A. (University of Huddersfield. Department of Chemical Sciences) ; Alba Castellón, Lorena (Institut d'Investigació Biomèdica Sant Pau) ; Álamo, Patricia (Institut d'Investigació Biomèdica Sant Pau) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Vázquez Gómez, Esther (Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Casanova Rigat, Isolda (Institut d'Investigació Biomèdica Sant Pau) ; Mangues, Ramon (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Background: current acute myeloid leukemia (AML) therapy fails to eliminate quiescent leukemic blasts in the bone marrow, leading to about 50% of patient relapse by increasing AML burden in the bone marrow, blood, and extramedullar sites. [...]
2020 - 10.1186/s13045-020-00863-9
Journal of hematology & oncology, Vol. 13 issue 1 (April 2020) , art. 36  
4.
11 p, 1.8 MB Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma / Munir, T. (Department of Haematology. St. James's University Hospital) ; Brown, J.R. (CLL Center. Dana-Farber Cancer Institute) ; O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ; Barrientos, J.C. (Division of Medical Oncology and Hematology Northwell Health Cancer Institute) ; Barr, P.M. (Wilmot Cancer Institute. University of Rochester Medical Center) ; Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ; Coutre, S. (Stanford Cancer Center. Stanford University School of Medicine) ; Tam, C.S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ; Mulligan, S.P. (Royal North Shore Hospital) ; Jaeger, U. (Division of Hematology and Hemostaseology. Medical University of Vienna) ; Kipps, T.J. (UCSD Moores Cancer Center) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Montillo, M. (Niguarda Ca' Granda Hospital) ; Burger, J.A. (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Byrd, J.C. (The Ohio State University Comprehensive Cancer Center) ; Hillmen, P. (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Dai, S. (Pharmacyclics LLC. an AbbVie Company) ; Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ; Dean, J.P. (Pharmacyclics LLC. an AbbVie Company) ; Woyach, J.A. (The Ohio State University Comprehensive Cancer Center) ; Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363  
5.
10 p, 1.6 MB International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting / El-Beshlawy, Amal (Cairo University) ; Inusa, Baba (Evelina Children's Hospital) ; Beneitez Pastor, David (Hospital Universitari Vall d'Hebron. Departament d'Hematologia) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Duran Nieto, Maria Soledad (Hospital Materno Infantil de Jaén) ; Bruederle, Andreas (Novartis Pharma AG) ; Azmon, Amin (Novartis Pharma AG, Switzerland) ; Gilotti, Geralyn (Novartis Pharmaceuticals Corporation, USA) ; Elalfy, Mohsen (Ain Shams University, Cairo) ; Universitat Autònoma de Barcelona
Objective:The study evaluates the long-term deferasirox treatment of adult and pediatricpatients with chronic transfusional iron overload in clinical practice. Methods:In this non-interventional study, patients were observed for up to 3 years frominitiation of deferasirox treatment both prospectively and retrospectively for up to 1 yearprior to enrollment. [...]
2019 - 10.1080/16078454.2018.1558758
Hematology, 2019  
6.
13 p, 2.7 MB Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia / Gökbuget, Nicola (Department of Medicine II, Department of Hematology/Oncology, University Hospital, Frankfurt, Germany) ; Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ; Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ; Bruggemann, Monika (Department of Hematology and Oncology, University Hospital Schleswig-Holstein) ; Doubek, Michael (Department of Internal Medicine, Hematology and Oncology,University Hospital, Brno, Czech Republic) ; Foà, Robin (Sapienza University of Rome) ; Hoelzer, Dieter (Department of Medicine II, Department of Hematology/Oncology, University Hospital, Frankfurt, Germany) ; Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ; Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ; Parovichnikova, Elena (National Research Center for Hematology, Moscow) ; Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ; Ribera, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Schoonen, Marieke (Amgen Ltd, London) ; Stieglmaier, Julia M. (Amgen GmBH, Munich) ; Zugmaier, Gerhard (Amgen GmBH, Munich) ; Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ; Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348  
7.
10 p, 809.5 KB The MUK five protocol : a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma / Brown, Sarah (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Hinsley, Samantha (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Ballesteros, Mónica (Universitat Autònoma de Barcelona, Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ; Bourne, Sue (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; McGarry, Paul (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Sherratt, Debbie (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Flanagan, Louise (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Gregory, Walter (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Cavenagh, Jamie (Department of Haematology, St Bartholomew's Hospital, London, UK) ; Owen, Roger (HMDS Laboratory, St James's University Hospital, Leeds, UK) ; Williams, Cathy (Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, UK) ; Kaiser, Martin (The Institute of Cancer Research, Sutton, UK) ; Low, Eric (Myeloma UK, Edinburgh, UK) ; Yong, Kwee (UCL Cancer Institute, 72 Huntley Street, WC1E 6BT London, UK)
Multiple myeloma is a plasma cell tumour with an annual incidence in the UK of approximately 40-50 per million i. e. about 4500 new cases per annum. The triple combination cyclophosphamide, bortezomib (Velcade®) and dexamethasone (CVD) is an effective regimen at relapse and has emerged in recent years as the standard therapy at first relapse in the UK. [...]
2016 - 10.1186/s12878-016-0053-9
BMC Hematology, Vol. 16 (may 2016)  
8.
8 p, 455.0 KB Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial / Moran, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Enriqueta (Hospital Universitary de la Vall d'Hebron) ; Keedy, Vicki (Vanderbilt University Medical Center) ; Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ; Shepherd, Frances A (University of Toronto) ; Insa, Amelia (Hospital Clínico Universitario de Valencia) ; Brown, Holly (Merck & Co., Inc., Whitehouse Station) ; Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ; Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ; Reilly, John F (Merck & Co., Inc., Whitehouse Station) ; Mauro, David (Merck & Co., Inc., Whitehouse Station) ; Hsu, Karl (Sanofi Aventis) ; Yan, Li (Merck & Co., Inc., Whitehouse Station) ; Universitat Autònoma de Barcelona
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC). [...]
2014 - 10.1186/2162-3619-3-26
Experimental Hematology & Oncology, Vol. 3 (november 2014)  
9.
9 p, 316.0 KB Treatment of Adolescent and Young Adults with Acute Lymphoblastic Leukemia / Ribera, Josep-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ribera, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
The primary objective of this review was to update and discuss the current concepts and the results of the treatment of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA). After a brief consideration of the epidemiologic and clinicobiologic characteristics of ALL in the AYA population, the main retrospective comparative studies stating the superiority of pediatric over adult-based protocols were reviewed. [...]
2014 - 10.4084/MJHID.2014.052
Mediterranean Journal of Hematology and Infectious Diseases, Vol. 6 (july 2014)  
10.
11 p, 858.6 KB Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation / Baron, Frédéric (Université de Liège (Bèlgica)) ; Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ; Ruggeri, Annalisa (Hôpital Saint-Louis (Paris, França)) ; Mohty, Mohamad (Hôpital Saint-Antoine (Paris, França)) ; Sanz, Guillermo (Hospital Universitario y Politécnico La Fe (València, País Valencià)) ; Milpied, Noel (Hôpital Haut Léveque (Pessac, França)) ; Bacigalupo, Andrea (Ospedale Sant Martino (Genova, Itàlia)) ; Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII (Bergamo, Itàlia)) ; Bonifazi, Francesca (Policlinico Sant'Orsola-Malpighi (Bologna, Itàlia)) ; Bosi, Alberto (Azienda Ospedaliero Universitaria Careggi (Firenze, Itàlia)) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Yakoub-Agha, Ibrahim (Hôpital Claude Huriez (Lille, França)) ; Ribera Santasusana, J. M. (José María) (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gluckman, Eliane (Hôpital Saint-Louis (Paris, França)) ; Nagler, Arnon (Sheba Medical Center (Ramat Gran, Israel)) ; Universitat Autònoma de Barcelona
BACKGROUND: In the setting of allogeneic human leukocyte antigen (HLA)-matched bone marrow transplantation, transplanting male patients with grafts from female donors has been associated with a higher incidence of graft-versus-host disease (GVHD) and of nonrelapse mortality (NRM). [...]
2015 - 10.1186/s13045-015-0207-4
Journal of hematology & oncology, Vol. 8 Núm. 107 (october 2015)  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.